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A recent article by Wang et al. elegantly synthesized new
nanoparticles consisting of cyclic guanosine
monophosphate–adenosine monophosphate (cGAMP), which
were administered alongside vaccines, to successfully deliver
into the lungs of animals leading to protection against
different subtypes of influenza infection without inflamma-
tory side effects.
Infections are common among everyday life.1 However, certain
infectious agents can cause widespread health and societal
burdens.2 A common problem with current vaccine treatments
is the inability to protect against the infection when it has
mutated owing to antigenic drift.3 Hence, there has always been a
long quest in the field of infection to discover treatment options
that will produce cross-protection (heterosubtypic immunity) to
infectious stereotypes. A method of providing this type of
protection is to activate the immune system in the early phase
of the infection without a chronic pathogenic inflammatory
response to the foreign particles (Fig. 1).
Type I interferons (IFN-Is) are produced by alveolar epithelial cells
(AECs) and immune cells to protect against infection.4 These genes
are activated by STING (stimulator of interferon genes). Past attempts
to target STING have failed owing to the inability to deliver STING
agonists into the cytosol of AECs without breaching the integrity of
the pulmonary surfactant (PS). Wang et al. hypothesized that
nanoparticles consisting of cGAMP, an agonist of STING alongside
an adjuvanted H1N1 vaccine, will induce an immune response by
CD8+ T cells, which can yield heterosubtypic immunity.5
The authors at first successfully synthesized nanoparticles with
the correct size, function, and safety. They tested the effects of the
nanoparticles in vitro (bone marrow-derived macrophages) and in
an in vivo model of infection. These results imply that the
nanoparticles may be metabolically stable and have efficacy in
humans, but more clinical trials are required. The authors also
robustly showed that the protective effects of the nanoparticles
did not occur in STING-deficient mice confirming that cGAMP,
rather than any other constituents, was responsible for PS-GAMP
adjuvanticity. The authors then went on to demonstrate that the
nanoparticles uptake was specific to the lung, which suggested
that there is a natural and molecule-specific mechanism of particle
clearance in the lung that would sustain the integrity of the PS
and alveolar epithelial barriers.
The next set of experiments demonstrated that the uptake of
nanoparticles was only confined to the lungs of mice. In addition,
there was no adverse inflammatory response in any body part and
serum cytokines (IFN-β, IFN-γ, interleukin (IL)-6, IL-10, and tumor
necrosis factor-α) levels did not change alongside mouse body
weight and temperature. Moreover, the inclusion of PS-GAMP
nanoparticles in the vaccination fully protected mice and ferrets
from homologous viral challenges as early as 2 days after
immunization in models of infection. Wang et al. went on to use
gap junction blocking drugs to show that there is a gap
junction–mediated flux of cGAMP to AECs from alveolar macro-
phages (AMs). These results empathised that the AECs rather than
AMs appear to be essential in orchestrating innate and adaptive
immune responses in the respiratory system during viral infection
and determining the potency of PS-GAMP.
The final set of experiments in the article were conducted to
determine whether the PS-GAMP nanoparticles alongside the
influenza vaccination can protect against a number of different
subtypes of the influenza viruses (heterosubtypic H3N2, H5N1,
and H7N9 viruses). Mice receiving vaccines together with PS-
GAMP were protected from challenges of different subtypes of the
influenza viruses by CD8+ TRM cells, rather than circulating
memory CD8+ T cells. Most importantly, these in vivo results
suggested that the nanoparticles plus vaccine approach was
similarly effective for both influenza A and B viral vaccines. Finally,
the authors successfully repeated the long-term heterosubtypic
protection induced by the dual PS-GAMP and vaccine treatment in
a ferret model of infection.
In summary, Wang et al. elegantly demonstrated nanoparticles
consisting of cGAMP, an agonist of STING, helped augment
adjuvanted H1N1 vaccine–induced humoral and CD8+ T cell
immune responses. This early activation did not elicit a pathogenic
inflammatory response but in fact protected against the H1N1 and
heterosubtypic H3N2, H5N1, and H7N9 viruses for at least
6 months while maintaining lung-resident memory CD8+ T cells.
The authors further showed that, when AECs lacked Sting or gap
junctions were blocked, PS-GAMP–mediated adjuvanticity did not
function in vivo. Overall, the studies by Wang et al. will be central
to how new vaccines and augmented therapies will be designed
and administered in the future. The ferret models used through-
out the paper suggest the potential for the approach in humans,
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but clinical trials are required. Nonetheless, these fundamental key
findings can possibly help create a new generation of treatments
that can protect against viral mutations in early infection to stop
the spread of different respiratory viruses, not only influenza
viruses, and cease global pandemics.
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Fig. 1 Current vaccines (inactivated flu vaccines) help by boosting immunity against one subtype of influenza virus. However, this approach
means seasonal and regular vaccines are required to combat the constant mutations caused by antigenic drift. Wang et al. showed
augmenting current vaccines with a new nanoparticle (PS-GAMP) that can activate long-term immunity against different subtypes of influenza
viruses (heterosubtypic influenza immunity). The results also hold promise to use this type of technology for universal vaccines against other
respiratory viruses
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